Extracellular matrix based surgical mesh materials have been used clinically for decades. ECM Therapeutics’ innovative platform technology, the ECM hydrogel, is prepared from the whole ECM with tailorable properties customized to product performance specifications. ECMT’s extensive patent portfolio is backed by years of preclinical and clinical research with data supporting the safety and effectiveness of the extracellular matrix in an injectable, moldable formula. Using proprietary decellularization technology, ECMT’s hydrogel provides a minimally invasive alternative to ECM mesh materials expanding the clinical utility of ECM biomaterials including targeting hard-to-reach and irregularly shaped areas, coatings, and void filling without the need for surgical mesh placement. ECM hydrogels retain structural and biologic milieu of native tissue while providing an inductive template for tissue remodeling to resolve disease and injury.